Ads
related to: biogen's- Understanding ALS
Read About ALS Symptoms
And Treatment
- ALS Treatment Results
Watch A Video on ALS
Treatment Efficacy & Safety
- Sign Up Today
Receive Information On
An ALS Treatment
- ALS Treatment Information
View Info On Dosing,
Clinical Data And FAQs
- Understanding ALS
Search results
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against...
Morningstar· 7 hours agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Biogen Inc. (NASDAQ: BIIB ...
UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law...
Morningstar· 13 hours agoNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Morningstar· 2 days agoGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB) Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 22, 2024 deadline to file a lead plaintiff motion in
European Commission approves Biogen’s QALSODY for ALS treatment
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe European Commission (EC) has granted marketing authorisation for Biogen's QALSODY (tofersen) an...
European Commission grants marketing approval to Biogen's ALS drug
Reuters via Yahoo News· 6 days agoThe approval is based on a 108-patient trial that showed Qalsody reduced levels of a neurofilament...
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Guru Focus· 6 days agoLong-established in the Drug Manufacturers industry, Biogen Inc (BIIB, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth, and valuation ...
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Benzinga via Yahoo Finance· 6 days agoOn Thursday, the European Commission granted marketing authorization under exceptional circumstances...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoCaptioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen as well as certain of Biogen’s top current and ...
Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class...
Morningstar· 23 hours agoNEW YORK, June 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 6 days agoBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen ...
